Somatostatin

CAS: 38916-34-6

Ref. 3D-HOR-299

Produktinformation

• Name: Somatostatin
• Synonyme: Growth hormone release-inhibiting factor, SST, SMS, SMST, GHIH, H-Ala-Gly-Cys-Lys-Asn-Phe-Phe-Trp-Lys-Thr-Phe-Thr-Ser-Cys-OH, So, 1: PN: US20020156010 PAGE: 3 unclaimed protein, 15: PN: WO2007081792 SEQID: 30 claimed protein, 15-28-Somatostatin-28, 243: PN: EP1170021 SEQID: 2 claimed protein, 34: PN: WO2007058336 SEQID: 34 claimed protein, Cyclic growth hormone release-inhibiting hormone, Cyclic ovine somatostatin, Cyclic somatostatin, Cyclic somatostatin-14, Cyclic somatotropin release-inhibitor factor, Cyclic tetradecapeptide somatostatin, Lampetra fluviatilis somatostatin-14, Somatostatin (Amphiuma tridactylum), Somatostatin (Anguilla anguilla), Somatostatin (Gopherus agassizii), Somatostatin (human), Somatostatin (Lophius americanus), Somatostatin (Myxine glutinosa), Somatostatin (pigeon), Somatostatin (rat), Somatostatin (sheep reduced), cyclic (3→14)-disulfide, Somatostatin I (Lophius americanus), Somatostatin SS-14, Somatostatin-14 (Gopherus agassizii), Somatostatin-14 (sheep), Somatostatina, Somatostatine, Sr 9357, Sst 14, Stilamin, Synthetic cyclic growth hormone release-inhibiting factor, Synthetic cyclic growth hormone release-inhibiting hormone, Synthetic growth hormone release-inhibiting hormone, Synthetic somatostatin-14

Beschreibung

Somatostatin is a peptide hormone that is produced by the hypothalamus and inhibits the release of growth hormones, stimulates the release of insulin from the pancreas, and inhibits the release of glucagon from the pancreas. Somatostatin also has biological properties that inhibit neuronal death in combination therapy groups. It has been shown to have cell factor activity which may contribute to its antitumor activity. Somatostatin also has pro-apoptotic properties in vitro assays at physiological levels, making it an excellent target for cancer therapy.

• Marke: Biosynth

Chemische Eigenschaften

• Molekulargewicht: 1,637.9 g/mol
• Formel: C₇₆H₁₀₄N₁₈O₁₉S₂
• Reinheit: Min. 95%